US, EU and Japanese pharmaceutical industry associations lambasted the European’s Commission proposal to establish a compulsory licensing (CL) scheme for drugs and vaccines in an emergency, asserting ...

A US-based trade group wants to see the United States Trade Representative (USTR) pursue stricter limits on the ability of countries to bypass patent protection. In its Special 301 Submission 2015, ...

Biopharma companies can minimise the threat of compulsory licensing by taking strategic steps that benefit both business and patients, says April Abele Isaacson of Kilpatrick Townsend Even though the ...

Compulsory licensing has been widely suggested as a legal mechanism for bypassing patents to introduce lower-cost generic antiretrovirals for HIV/AIDS in developing countries. Previous studies found ...

After compulsory licenses were pursued for erlotinib, letrozole, and doxcetaxel in Thailand, there were clear benefits in terms of reducing drug costs and improving access to treatments for patients ...

Although Pfizer Inc.’s COVID-19 oral antiviral candidate, Paxlovid (PF-07321332; ritonavir), has yet to be authorized anywhere, the push for compulsory licensing of the drug has begun.

With the next Supreme Court term beginning in a few weeks we all need to come to terms with the fact that the U.S. has a compulsory licensing system, which is truly ironic. Trade missions, trade ...